Signatera Looks Deeper
Real-world examples of Signatera for immunotherapy monitoring
ON-DEMAND WEBINAR
Learn about how Signatera can be used to assess treatment response to immunotherapy
Clinical applications of ctDNA testing for Immunotherapy response monitoring
Luis E. Raez, MD, FACP, FCCP, CSO
Medical Director and Chief Scientific Officer, Memorial Cancer Institute, Florida
POSTER PRESENTATION
-
Circulating tumor DNA (ctDNA) serial analysis during progression on PD-1 blockade and later CTLA-4 rescue in patients with mismatch repair deficient metastatic colorectal cancer
Abstract ID: 23 -
Utility of tumor-informed molecular residual disease assays in patients with complete response to immune checkpoint blockade
Abstract ID: 24 -
Line of therapy adjustment in a patient with advanced triple-negative breast cancer (TNBC) by using personalized ctDNA test for treatment response monitoring
Abstract ID: 25 -
ctDNA clearance and radiographic resolution of lymph node metastasis in a patient with metastatic microsatellite stable colorectal cancer on immunotherapy
Abstract ID: 26
Dive Deeper
ctDNA and MRD Testing | Colorectal Cancer Care Tools for Surveillance
Video
Seeing beyond the limit: Detect residual disease and assess treatment response
Whitepaper
A personalized, tumor informed approach to detect molecular residual disease with high sensitivity and specificity
Whitepaper